Nilotinib Viatris (Nilotinib)

• Nilotinib is a targeted therapy used in the treatment of hematologic malignancies driven by the BCR‑ABL fusion protein.
• Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and achieves cytogenetic response.
• Accelerated or blast phase CML: helps attain hematologic and molecular remission.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia: contributes to disease control and remission in adult patients.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, a constitutively active enzyme produced by the Philadelphia chromosome translocation. By binding to the ATP‑binding site, it blocks downstream signaling pathways that drive cell proliferation. The drug also inhibits related kinases such as c‑KIT and PDGFR, further limiting malignant cell growth and inducing apoptosis in leukemic cells. This targeted inhibition results in reduced disease progression and improved survival outcomes in patients with BCR‑ABL‑positive leukemias.

Nilotinib may cause a range of adverse reactions, varying from mild to potentially serious.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools that may lead to dehydration.
• Rash: skin irritation or erythema.
• Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects

• QT interval prolongation: may cause cardiac arrhythmias.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
• Severe liver injury: elevated transaminases or hepatitis.
• Hematologic toxicity: neutropenia, thrombocytopenia, or anemia.

Before initiating Nilotinib therapy, several safety considerations should be evaluated.

• Cardiac monitoring: obtain baseline ECG and assess QT interval regularly.
• Liver function: check hepatic enzymes and adjust therapy if significant elevation occurs.
• Blood counts: monitor complete blood count for neutropenia or thrombocytopenia.
• Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors or QT‑prolonging agents.
• Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Nilotinib interacts with several medicines that can alter its effectiveness or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Nilotinib levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure.
• QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of cardiac arrhythmias.
• Antacids containing aluminum or magnesium: decrease absorption of Nilotinib.
• Warfarin: may enhance anticoagulant effect and raise INR.

Moderate Interactions (Monitor Closely)

• Digoxin: possible increase in serum concentration.
• Statins (simvastatin, lovastatin): may require dose adjustment due to metabolic overlap.